Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum

chronic kidney disease

  • DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants
    You have accessRestricted Access
    DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants
    Justin Chun, Cristian V. Riella, Hyunjae Chung, Shrijal S. Shah, Minxian Wang, Jose M. Magraner, Guilherme T. Ribas, Hennrique T. Ribas, Jia-Yue Zhang, Seth. L. Alper, David J. Friedman and Martin R. Pollak
    JASN May 2022, 33 (5) 889-907; DOI: https://doi.org/10.1681/ASN.2021050723
    Add to Selected Citations
  • You have accessRestricted Access
    Longitudinal TNFR1 and TNFR2 and Kidney Outcomes: Results from AASK and VA NEPHRON-D
    Teresa K. Chen, Steven G. Coca, Michelle M. Estrella, Lawrence J. Appel, Josef Coresh, Heather Thiessen Philbrook, Wassim Obeid, Linda F. Fried, Hiddo J.L. Heerspink, Joachim H. Ix, Michael G. Shlipak, Paul L. Kimmel, Chirag R. Parikh and Morgan E. Grams; on behalf of the CKD Biomarkers Consortium (BioCon)
    JASN May 2022, 33 (5) 996-1010; DOI: https://doi.org/10.1681/ASN.2021060735
    Add to Selected Citations
  • You have accessRestricted Access
    The Search for the Perfect Agent for Anemia Management in Chronic Kidney Disease
    Francesco Locatelli and Lucia Del Vecchio
    JASN April 2022, 33 (4) 662-664; DOI: https://doi.org/10.1681/ASN.2022020173
    Add to Selected Citations
  • A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome
    Open Access
    A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome
    Anissa A. Widjaja, Shamini G. Shekeran, Eleonora Adami, Joyce G Wei Ting, Jessie Tan, Sivakumar Viswanathan, Sze Yun Lim, Puay Hoon Tan, Norbert Hübner, Thomas Coffman and Stuart A. Cook
    JASN April 2022, 33 (4) 718-730; DOI: https://doi.org/10.1681/ASN.2021040577
    Add to Selected Citations
  • Decreased Renal Gluconeogenesis Is a Hallmark of Chronic Kidney Disease
    You have accessRestricted Access
    Decreased Renal Gluconeogenesis Is a Hallmark of Chronic Kidney Disease
    Thomas Verissimo, Anna Faivre, Anna Rinaldi, Maja Lindenmeyer, Vasiliki Delitsikou, Christelle Veyrat-Durebex, Carolyn Heckenmeyer, Marylise Fernandez, Lena Berchtold, Delal Dalga, Clemens Cohen, Maarten Naesens, Sven-Erik Ricksten, Pierre-Yves Martin, Jérôme Pugin, Franck Merlier, Karsten Haupt, Joseph M. Rutkowski, Solange Moll, Pietro E. Cippà, David Legouis and Sophie de Seigneux
    JASN April 2022, 33 (4) 810-827; DOI: https://doi.org/10.1681/ASN.2021050680
    Add to Selected Citations
  • Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
    Open Access
    Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study
    Steven Fishbane, Carol A. Pollock, Mohamed El-Shahawy, Elizabeth T. Escudero, Anjay Rastogi, Bui Pham Van, Lars Frison, Mark Houser, Maksym Pola, Dustin J. Little, Nicolas Guzman and Pablo E. Pergola
    JASN April 2022, 33 (4) 850-866; DOI: https://doi.org/10.1681/ASN.2020111638
    Add to Selected Citations
  • Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study
    You have accessRestricted Access
    Risk Prediction Models for Atherosclerotic Cardiovascular Disease in Patients with Chronic Kidney Disease: The CRIC Study
    Joshua D. Bundy, Mahboob Rahman, Kunihiro Matsushita, Byron C. Jaeger, Jordana B. Cohen, Jing Chen, Rajat Deo, Mirela A. Dobre, Harold I. Feldman, John Flack, Radhakrishna R. Kallem, James P. Lash, Stephen Seliger, Tariq Shafi, Shoshana J. Weiner, Myles Wolf, Wei Yang, Norrina B. Allen, Nisha Bansal, Jiang He and the CRIC Study Investigators*
    JASN March 2022, 33 (3) 601-611; DOI: https://doi.org/10.1681/ASN.2021060747
    Add to Selected Citations
  • Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury
    You have accessRestricted Access
    Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury
    Sherry G. Mansour, Pavan K. Bhatraju, Steven G. Coca, Wassim Obeid, Francis P. Wilson, Ian B. Stanaway, Yaqi Jia, Heather Thiessen-Philbrook, Alan S. Go, T. Alp Ikizler, Edward D. Siew, Vernon M. Chinchilli, Chi-yuan Hsu, Amit X. Garg, W. Brian Reeves, Kathleen D. Liu, Paul L. Kimmel, James S. Kaufman, Mark M. Wurfel, Jonathan Himmelfarb, Samir M. Parikh, Chirag R. Parikh and for the ASSESS-AKI Consortium*
    JASN March 2022, 33 (3) 613-627; DOI: https://doi.org/10.1681/ASN.2021060757
    Add to Selected Citations
  • You have accessRestricted Access
    Autoimmune Podocytopathies: A Novel Sub-Group of Diseases from Childhood Idiopathic Nephrotic Syndrome
    Qing Ye, Anqun Chen, En Yin Lai and Jianhua Mao
    JASN March 2022, 33 (3) 653-654; DOI: https://doi.org/10.1681/ASN.2021111469
    Add to Selected Citations
  • You have accessRestricted Access
    Authors’ Reply
    Andrew J.B. Watts, Keith H. Keller and Astrid Weins
    JASN March 2022, 33 (3) 654; DOI: https://doi.org/10.1681/ASN.2021121540
    Add to Selected Citations

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 39

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire